These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3549083)

  • 1. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis.
    Woo KT; Edmondson RP; Yap HK; Wu AY; Chiang GS; Lee EJ; Pwee HS; Lim CH
    Clin Nephrol; 1987 Feb; 27(2):56-64. PubMed ID: 3549083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later.
    Woo KT; Lee GS; Lau YK; Chiang GS; Lim CH
    Clin Nephrol; 1991 Aug; 36(2):60-6. PubMed ID: 1934661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
    Walker RG; Yu SH; Owen JE; Kincaid-Smith P
    Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis.
    Murphy BF; McDonald I; Fairley KF; Kincaid-Smith PS
    Clin Nephrol; 1992 May; 37(5):229-34. PubMed ID: 1606772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of ligustrazine on proliferative glomerulonephritis].
    Tang X
    Zhong Yao Cai; 2003 Aug; 26(8):611-2. PubMed ID: 14649206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin.
    Woo KT; Lee GS
    Clin Nephrol; 1991 Apr; 35(4):184. PubMed ID: 1855324
    [No Abstract]   [Full Text] [Related]  

  • 8. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
    Yoshikawa N; Honda M; Iijima K; Awazu M; Hattori S; Nakanishi K; Ito H;
    Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment.
    Lee GS; Woo KT; Lim CH
    Clin Nephrol; 1989 May; 31(5):276. PubMed ID: 2661066
    [No Abstract]   [Full Text] [Related]  

  • 10. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
    Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
    Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combined immunosuppressive anticoagulant and antiplatelet therapy of the course of chronic mesangial-proliferative glomerulonephritis.
    Matousovic K; Matl I; Zabka J; Zástava V; Rossmann P; Prát V
    Czech Med; 1985; 8(3):151-7. PubMed ID: 3932033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide.
    Brodsky SV; Rovin BH; Hebert LA
    Nephrol Dial Transplant; 2012 Feb; 27(2):475-7. PubMed ID: 21948859
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of IgA nephritis showing diffuse podocytic detachment from the glomerular basement membrane.
    Moriya T; Nakazawa K; Itoh N; Shigematsu H; Higuchi M; Miyasaka M; Oguchi H
    Nihon Jinzo Gakkai Shi; 1992 Apr; 34(4):423-30. PubMed ID: 1635288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
    Shearman JD; Yin ZG; Aarons I; Smith PS; Woodroffe AJ; Clarkson AR
    Clin Nephrol; 1988 Dec; 30(6):320-9. PubMed ID: 3243041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
    Tsuruya K; Harada A; Hirakata H; Mitsuiki K; Johko T; Kondoh H; Takechi S; Fujishima M
    Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term administration of cyclosporine A in patients with IgA nephropathy].
    Chábová V; Tesar V; Zabka J; Rychlík I; Merta M; Jirsa M; Stejskalová A; Stejskal J
    Cas Lek Cesk; 1996 Dec; 135(24):803-6. PubMed ID: 9072300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review.
    Fernandes PF; Júnior GB; Barros FA; Sousa DC; Franco LM; Patrocínio RM
    Invest Clin; 2006 Dec; 47(4):405-11. PubMed ID: 17176908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive treatment of Berger's disease.
    Faedda R; Pirisi M; Satta A; Bosincu L; Bartoli E
    Clin Pharmacol Ther; 1996 Nov; 60(5):561-7. PubMed ID: 8941029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy in children and adolescents with IgA nephropathy.
    Murakami K; Yoshioka K; Akano N; Takemura T; Okada M; Aya N; Hino S; Miyazato H; Yagi K; Maki S
    Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):38-43. PubMed ID: 8107307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
    Kanno Y; Okada H; Saruta T; Suzuki H
    Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.